Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma

Table 2 Univariate and multivariate Cox regression analyses for OS.

Characteristic	Univariate analysis			Multivariate analysis
Characteristic	HR	95%CI	P	HR	95%CI	P
Child–Pugh classification(B/A)	0.446	0.210 ∼ 0.951	0.037	0.658	0.289 ∼ 1.499	0.319
No. of tumors (≥ 3/<3)	1.191	0.671 ∼ 2.114	0.550
Tumor diameter (≥ 5 cm/ <5 cm)	0.873	0.489 ∼ 1.561	0.648
Portal vein tumor thrombus (yes/no)	2.881	1.389 ∼ 5.975	0.004	1.913	0.868 ∼ 4.214	0.107
Extrahepatic metastases (yes/no)	1.203	0.645 ∼ 2.244	0.562
AFP (≥ 400ng/mL/ < 400ng/mL)	1.914	1.132 ∼ 3.234	0.015	1.608	0.929 ∼ 2.782	0.089
Treatment option (TACE + T/TACE + TC)	2.056	1.194 ∼ 3.540	0.009	2.013	1.162 ∼ 3.489	0.013
Interval of recurrence from initial treatment(<1 year/≥1 year)	0.473	0.248 ∼ 0.900	0.023	0.534	0.277 ∼ 1.030	0.061
MVI(Positive/Negative)	1.109	0.658 ∼ 1.869	0.699

AFP, a-fetoprotein; MVI, microvascular invasion; No. of tumors, number of tumors.

ISSN: 1471-2407